Key clinical point: The novel CDK inhibitor flavopiridol showed minimal efficacy in patients with relapsed/refractory mantle cell lymphoma, diffuse large B-cell lymphoma, and other B-cell lymphomas.
Major finding: Of 26 evaluable patients, one patient with DLBCL maintained a partial response for 84 days (overall response rate, 3.8%).
Study details: A phase 1/2 study of 28 patients with relapsed/refractory MCL and DLBCL.
Disclosures: The trial is sponsored by the National Cancer Institute, and the study authors are employees of the National Cancer Institute.
Miljkovic MD et al. Leuk Lymphoma. 2019 Jun 17. doi: 10.1080/10428194.2019.1627540.